/GLMD
GLMD Stock - Galmed Pharmaceuticals Ltd.
Healthcare|BiotechnologyNASDAQ
$0.85-4.24%
$0.04 (-4.24%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.94
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.84 – $0.86
TARGET (TP)$0.98
STOP LOSS$0.78
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$3.61
52W Low$0.74
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-83,000 | $-31,000 | $-35,000 | $-42,000 | $-39,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,278,000 | $7.49M | $-17,651,000 | $-32,881,000 | $-30,210,000 |
| Net Income | $-7,517,000 | $-6,912,000 | $-18,571,000 | $-31,948,000 | $-27,610,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-8.08 | $-30.05 | $-11.08 | $-19.48 | $-19.46 |
Company Overview
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GLMDBeat Rate
57%
Last 14 quarters
Avg Surprise
-1500.1%
EPS vs Estimate
Beats / Misses
8/6
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q2 24
-3575.0%
$-11.76vs$-0.32
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
+30.3%
$-0.62vs$-0.89
Q3 25
+175.9%
$0.63vs$-0.83
Q4 25
+38.9%
$-0.33vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 20, 2026 | — | — | — | — |
Q4 2025 | Nov 26, 2025 | $-0.54 | $-0.33 | +38.9% | ✓ BEAT |
Q3 2025 | Aug 28, 2025 | $-0.83 | $0.63 | +175.9% | ✓ BEAT |
Q2 2025 | May 22, 2025 | $-0.89 | $-0.62 | +30.3% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | — | $-11.76 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-2.31 | — | — |
Q3 2024 | Aug 28, 2024 | — | $2.16 | — | — |
Q2 2024 | May 30, 2024 | — | $-2.76 | — | — |
Q2 2024 | Apr 4, 2024 | $-0.32 | $-11.76 | -3575.0% | ✗ MISS |
Q4 2023 | Nov 22, 2023 | $-0.27 | $-2.88 | -966.7% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.34 | $-11.40 | -3252.9% | ✗ MISS |
Q2 2023 | Jun 1, 2023 | $-1.50 | $-13.09 | -772.7% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $-0.14 | $-18.00 | -12757.1% | ✗ MISS |
Q4 2022 | Nov 16, 2022 | $-27.00 | $-37.80 | -40.0% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-41.40 | $-27.00 | +34.8% | ✓ BEAT |
Q2 2022 | May 17, 2022 | $-59.39 | $-43.20 | +27.3% | ✓ BEAT |
Q2 2022 | May 2, 2022 | — | $-4.45 | — | — |
Q4 2021 | Nov 8, 2021 | $-71.99 | $-55.79 | +22.5% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-73.79 | $-59.39 | +19.5% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-79.19 | $-68.39 | +13.6% | ✓ BEAT |
Latest News
Galmed Pharmaceuticals Presents Late-Breaking Abstract At HEP-DART 2025 Meeting
📈 PositiveBenzinga•Dec 8, 2025, 01:32 PM
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
📈 PositiveBenzinga•Dec 4, 2025, 01:36 PM
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate
📈 PositiveBenzinga•Nov 26, 2025, 01:34 PM
GLMD stock has given up its prior gain. Galmed Pharmaceuticals shares were trading higher after the company announced top-line results from Galmed's AM-001 Study, a Phase 1 Bioavailability Study of Aramchol meglumine.
➖ NeutralBenzinga•Nov 18, 2025, 05:27 PM
Galmed Pharmaceuticals shares are trading higher after the company announced top-line results from Galmed's AM-001 Study, a Phase 1 Bioavailability Study of Aramchol meglumine.
📈 PositiveBenzinga•Nov 18, 2025, 02:06 PM
Galmed Pharmaceuticals Reports Top-Line Results From AM-001 Phase 1 Bioavailability Study, Demonstrating Enhanced Pharmacokinetic Profile Of Aramchol Meglumine Granules
📈 PositiveBenzinga•Nov 18, 2025, 01:44 PM
Galmed Announces Top Line Results From AM-001 Study Of Aramchol Meglumine, Showing Bioavailability Of Aramchol Meglumine 400mg And 200mg Granules Is Higher Than That Of Aramchol Free Acid 300mg Tablets
📈 PositiveBenzinga•Nov 18, 2025, 01:43 PM
Galmed Announces Top Line Results From AM-001 Study Of Aramchol Meglumine showing Bioavailability Of Aramchol Meglumine 400mg And 200mg Granules Is Hither Than That Of Aramchol Free Acid 300mg Tablets
📈 PositiveBenzinga•Nov 18, 2025, 01:40 PM
Galmed Announces Top-line Results From Oncology MoA Studies Showing Combination Of Aramchol, Stivarga And Metformin Enhanced GI Tumor Cells, Killing In-vivo And In-vitro
📈 PositiveBenzinga•Nov 17, 2025, 01:32 PM
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
📈 PositiveBenzinga•Aug 28, 2025, 01:36 PM
Galmed Board Approves Digital Asset Management Strategy Including Potential Allocation Of Up To 50% Of Cash Reserves To Be Used For Digital Asset Purchases
➖ NeutralBenzinga•Aug 25, 2025, 11:37 AM
Frequently Asked Questions about GLMD
What is GLMD's current stock price?
Galmed Pharmaceuticals Ltd. (GLMD) is currently trading at $0.85 per share. The stock has moved -4.24% today.
What is the analyst price target for GLMD?
No analyst price targets are currently available for this stock.
What sector is Galmed Pharmaceuticals Ltd. in?
Galmed Pharmaceuticals Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GLMD's market cap?
Galmed Pharmaceuticals Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does GLMD pay dividends?
No, Galmed Pharmaceuticals Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
BIVI
BioVie Inc.
$1.41
Mkt Cap: $0.0B
CMMB
Chemomab Therapeutics Ltd.
$1.89
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
ISPC
iSpecimen Inc.
$0.37
Mkt Cap: $0.0B
MLEC
Moolec Science S.A.
$0.33
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
TOVX
Theriva Biologics, Inc.
$0.19
Mkt Cap: $0.0B
VRAX
Virax Biolabs Group Limited
$0.39
Mkt Cap: $0.0B
Explore stocks similar to GLMD for comparison